Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Open accessThe DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.
Abstract
Histone deacetylases (HDACs) can regulate expression of tumor suppressor genes and activities of transcriptional factors involved in both cancer initiation and progression through alteration of either DNA or the structural components of chromatin. Recently, the role of gene repression through modulation such as acetylation in cancer patients has been clinically validated with several inhibitors of HDACs. One of the HDAC inhibitors, vorinostat, has been approved by FDA for treating cutaneous T-cell lymphoma (CTCL) for patients with progressive, persistent, or recurrent disease on or following two systemic therapies. Other inhibitors, for example, FK228, PXD101, PCI-24781, ITF2357, MGCD0103, MS-275, valproic acid and LBH589 have also demonstrated therapeutic potential as monotherapy or combination with other anti-tumor drugs in CTCL and other malignancies. At least 80 clinical trials are underway, testing more than eleven different HDAC inhibitory agents including both hematological and solid malignancies. This review focuses on recent development in clinical trials testing HDAC inhibitors as anti-tumor agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain
Bannister, A. J., Zegerman, P., Partridge, J. F., Miska, E. A., Thomas, J. O., Allshire, R. C., & Kouzarides, T. (2001) · Nature · doi:10.1038/35065138 · Cited by 2,903
Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins
Lachner, M., O'Carroll, D., Rea, S., Mechtler, K., & Jenuwein, T. (2001) · Nature · doi:10.1038/35065132 · Cited by 2,868 · cited 1×
“A consequence of this alteration in nucleosome conformation is reduced accessibility of the transcriptional regulatory machinery to the DNA template, resulting in transcriptional repression [60-63].”
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 1×
“MS-275 is a synthetic benzamide derivative that has been shown to inhibit HDACs, and has anti-tumor activity in many preclinical models [25,85-88].”
Twenty-Five Years of the Nucleosome, Fundamental Particle of the Eukaryote Chromosome
Kornberg, R. D., & Lorch, Y. (1999) · Cell · doi:10.1016/s0092-8674(00)81958-3 · Cited by 1,830
Acetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584 · cited 1×
“Acetylation and deacetylation of sequence-specific transcription factors can either increase or decrease their DNA binding activity, and subsequently may enhance or repress transcription [64-68].”
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
Bali, P., Pranpat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K., Kumaraswamy, S., Boyapalle, S., Atadja, P., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500186200 · Cited by 755
Gao, L., Cueto, M. A., Asselbergs, F., & Atadja, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111871200 · Cited by 744 · cited 1×
“HDAC11 is located in both cytoplasm and nucleus and belongs to class IV [20].”
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070779 · Cited by 713
Regulation of activity of the transcription factor GATA-1 by acetylation
Boyes, J., Byfield, P., Nakatani, Y., & Ogryzko, V. (1998) · Nature · doi:10.1038/25166 · Cited by 694 · cited 1×
“Acetylation and deacetylation of sequence-specific transcription factors can either increase or decrease their DNA binding activity, and subsequently may enhance or repress transcription [64-68].”
HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics
Gallinari, P., Marco, S. D., Jones, P., Pallaoro, M., & Steinkühler, C. (2007) · Cell Research · doi:10.1038/sj.cr.7310149 · Cited by 678
Sandor, V. A., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, J., Brooks, R. A., Piekarz, R., Tucker, E. E., Figg, W. D., et al. (2002) · PubMed · Cited by 502
The diverse functions of histone acetyltransferase complexes
Carrozza, M. J., Utley, R. T., Workman, J. L., & Côté, J. (2003) · Trends in Genetics · doi:10.1016/s0168-9525(03)00115-x · Cited by 487
Prospects: Histone deacetylase inhibitors
Dokmanovic, M., & Marks, P. A. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20532 · Cited by 479
Garcia-Manero, G., Kantarjian, H. M., Sanchez-Gonzalez, B., Yang, H., Rosner, G., Verstovsek, S., Rytting, M., Wierda, W. G., Ravandi, F., Koller, C., et al. (2006) · Blood · doi:10.1182/blood-2006-03-009142 · Cited by 467
(2003) · PubMed · Cited by 465
Morschhauser, F., Radford, J., Van Hoof, A., Vitolo, U., Soubeyran, P., Tilly, H., Huijgens, P. C., Kolstad, A., d’Amore, F., Diaz, M. G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2015 · Cited by 460
Piekarz, R. L., Robey, R., Sandor, V., Bakke, S., Wilson, W. H., Dahmoush, L., Kingma, D. M., Turner, M. L., Altemus, R., & Bates, S. E. (2001) · Blood · doi:10.1182/blood.v98.9.2865 · Cited by 445
Class II Histone Deacetylases: from Sequence to Function, Regulation, and Clinical Implication
Yang, X.-J., & Grégoire, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.8.2873-2884.2005 · Cited by 419
Ryan, Q. C., Headlee, D., Acharya, M., Sparreboom, A., Trepel, J. B., Ye, J., Figg, W. D., Hwang, K., Chung, E. J., Murgo, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.188 · Cited by 411
Janot, F., de Raucourt, D., Benhamou, E., Ferron, C., Dolivet, G., Bensadoun, R.-J., Hamoir, M., Géry, B., Julieron, M., Castaing, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0102 · Cited by 405
Byrd, J. C. (2004) · Blood · doi:10.1182/blood-2004-05-1693 · Cited by 398
Soriano, A. O., Yang, H., Faderl, S., Estrov, Z., Giles, F., Ravandi, F., Cortes, J., Wierda, W. G., Ouzounian, S., Quezada, A., et al. (2007) · Blood · doi:10.1182/blood-2007-03-078576 · Cited by 390
Satelite Symposium V, Meet-the-Professor Sessions I and II, Main Sessions I-IX
(2004) · Annals of Hematology · doi:10.1007/s00277-004-0850-2 · Cited by 365
Cathepsin L Proteolytically Processes Histone H3 During Mouse Embryonic Stem Cell Differentiation
Duncan, E. M., Muratore-Schroeder, T. L., Cook, R. G., Garcia, B. A., Shabanowitz, J., Hunt, D. F., & Allis, C. D. (2008) · Cell · doi:10.1016/j.cell.2008.09.055 · Cited by 364
Isoform-selective histone deacetylase inhibitors
Bieliauskas, A. V., & Pflum, M. K. H. (2008) · Chemical Society Reviews · doi:10.1039/b703830p · Cited by 350
HDAC inhibitors: Clinical update and mechanism-based potential
Glaser, K. B. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.04.007 · Cited by 348
George, P., Bali, P., Annavarapu, S., Scuto, A., Fiskus, W., Guo, F., Sigua, C., Sondarva, G., Moscinski, L., Atadja, P., et al. (2005) · Blood · doi:10.1182/blood-2004-09-3413 · Cited by 324
Histone deacetylase inhibitors: discovery and development as anticancer agents
Marks, P. A., & Dokmanovic, M. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.12.1497 · Cited by 318
Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia
Blum, W., Klisovic, R. B., Hackanson, B., Liu, Z., Liu, S., Devine, H., Vukosavljevic, T., Huynh, L., Lozanski, G., Kefauver, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4169 · Cited by 315
Giles, F., Fischer, T., Cortes, J., Garcia-Manero, G., Beck, J., Ravandi, F., Masson, E., Rae, P., Laird, G., Sharma, S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0511 · Cited by 312
Histone deacetylase inhibitors in cancer treatment
Vigushin, D. M., & Coombes, R. C. (2002) · Anti-Cancer Drugs · doi:10.1097/00001813-200201000-00001 · Cited by 301
Structure and dynamic behavior of nucleosomes
Luger, K. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(03)00026-1 · Cited by 300
Ellis, L., Pan, Y., Smyth, G. K., George, D. J., McCormack, C., Williams-Truax, R., Mita, M., Beck, J., Burris, H., Ryan, G., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4262 · Cited by 297
Gojo, I., Jiemjit, A., Trepel, J. B., Sparreboom, A., Figg, W. D., Rollins, S., Tidwell, M. L., Greer, J., Chung, E. J., Lee, M.-J., et al. (2007) · Blood · doi:10.1182/blood-2006-05-021873 · Cited by 281
Qian, D. Z., Kato, Y., Shabbeer, S., Wei, Y., Verheul, H. M. W., Salumbides, B., Sanni, T., Atadja, P., & Pili, R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1132 · Cited by 268
Candelaria, M., Gallardo-Rincón, D., Arce, C., Cetina, L., Aguilar-Ponce, J. L., Arrieta, Ó., González-Fierro, A., Chávez-Blanco, A., de la Cruz-Hernández, E., Camargo, M. F., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm204 · Cited by 252
Steele, N. L., Plumb, J. A., Vidal, L., Tjørnelund, J., Knoblauch, P., Rasmussen, A., Ooi, C. E., Buhl-Jensen, P., Brown, R., Evans, T. R. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1786 · Cited by 244
Targeting histone deacetylase in cancer therapy
Lin, H., Chen, C., Lin, S., Weng, J., & Chen, C. (2006) · Medicinal Research Reviews · doi:10.1002/med.20056 · Cited by 241
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy
Yuan, R., Kay, A., Berg, W. J., & Lebwohl, D. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-45 · Cited by 240
Maiso, P., Carvajal-Vergara, X., Ocio, E. M., López-Pérez, R., Mateo, G., Gutiérrez, N., Atadja, P., Pandiella, A., & San Miguel, J. F. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4186 · Cited by 238
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination
Adimoolam, S., Sirisawad, M., Chen, J., Thiemann, P., Ford, J. M., & Buggy, J. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707828104 · Cited by 236
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
Garcia-Manero, G., Assouline, S., Cortes, J., Estrov, Z., Kantarjian, H., Yang, H., Newsome, W. M., Miller, W. H., Rousseau, C., Kalita, A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-115873 · Cited by 233
Nucleosome and chromatin fiber dynamics
Luger, K., & Hansen, J. C. (2005) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2005.03.006 · Cited by 227
Kuendgen, A., Schmid, M., Schlenk, R., Knipp, S., Hildebrandt, B., Steidl, C., Germing, U., Haas, R., Dohner, H., & Gattermann, N. (2006) · Cancer · doi:10.1002/cncr.21552 · Cited by 224
HDACs and HDAC inhibitors in colon cancer
Mariadason, J. M. (2008) · Epigenetics · doi:10.4161/epi.3.1.5736 · Cited by 222
Münster, P., Marchion, D., Bicaku, E., Schmitt, M., Lee, J. H., DeConti, R., Simon, G., Fishman, M., Minton, S., Garrett, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.6165 · Cited by 216
Inhibitors of Histone Deacetylase as New Anticancer Agents
Jung, M. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013372058 · Cited by 213
A phase I trial of Depsipeptide (FR901228) in patients with advanced cancer
Marshall, J. L., Rizvi, N., Kauh, J., Dahut, W., Figuera, M., Kang, M. H., Figg, W. D., Wainer, I., Chaissang, C., Zhaoyang Li, M., et al. (2002) · Journal of Experimental Therapeutics and Oncology · doi:10.1046/j.1359-4117.2002.01039.x · Cited by 204
Vorinostat in solid and hematologic malignancies
Siegel, D., Hussein, M., Belani, C., Robert, F., Galanis, E., Richon, V. M., Garcia-Vargas, J., Sanz-Rodriguez, C., & Rizvi, S. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-31 · Cited by 195
Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid
Camphausen, K., Cerna, D., Scott, T., Sproull, M., Burgan, W. E., Cerra, M. A., Fine, H., & Tofilon, P. J. (2005) · International Journal of Cancer · doi:10.1002/ijc.20774 · Cited by 190
Bug, G., Ritter, M., Wassmann, B., Schoch, C., Heinzel, T., Schwarz, K., Romanski, A., Kramer, O. H., Kampfmann, M., Hoelzer, D., et al. (2005) · Cancer · doi:10.1002/cncr.21589 · Cited by 184
Atmaca, A., Al-Batran, S.-E., Maurer, A., Neumann, A., Heinzel, T., Hentsch, B., Schwarz, S. E., Hövelmann, S., Göttlicher, M., Knuth, A., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603851 · Cited by 183
Welsbie, D. S., Xu, J., Chen, Y., Borsu, L., Scher, H. I., Rosen, N., & Sawyers, C. L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2216 · Cited by 182
The emerging role of class II histone deacetylases
Fischle, W., Kiermer, V., Dequiedt, F., & Verdin, E. (2001) · Biochemistry and Cell Biology · doi:10.1139/bcb-79-3-337 · Cited by 181
HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma
Singh, T. R., Shankar, S., & Srivastava, R. K. (2005) · Oncogene · doi:10.1038/sj.onc.1208585 · Cited by 177
Histone modifications and chromatin dynamics: a focus on filamentous fungi
Brosch, G., Loidl, P., & Graessle, S. (2008) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2007.00100.x · Cited by 173
Gore, L., Rothenberg, M. L., O'Bryant, C. L., Schultz, M. K., Sandler, A. B., Coffin, D., McCoy, C., Schott, A., Scholz, C., & Eckhardt, S. G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1461 · Cited by 171 · cited 1×
“The recommended dose for further disease-focused studies is 4 mg/m(2) given weekly for 3 weeks every 28 days or 2 to 6 mg/m(2) given once every other week [91].”
Coffey, D. C., Kutko, M. C., Glick, R. D., Butler, L. M., Heller, G., Rifkind, R. A., Marks, P. A., Richon, V. M., & LaQuaglia, M. P. (2001) · PubMed · Cited by 171
Luger, K. (2006) · Chromosome Research · doi:10.1007/s10577-005-1026-1 · Cited by 171
Hess‐Stumpp, H., Bracker, T. U., Henderson, D. A., & Politz, O. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.02.009 · Cited by 167
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F
Guerini, V., Barbui, V., Spinelli, O., Salvi, A., Dellacasa, C. M., Carobbio, A., Introna, M., Barbui, T., Golay, J., & Rambaldi, A. (2007) · Leukemia · doi:10.1038/sj.leu.2405049 · Cited by 164
Geng, L., Cuneo, K. C., Fu, A., Tu, T., Atadja, P. W., & Hallahan, D. E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0049 · Cited by 163
Shankar, S., & Srivastava, R. K. (2008) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4020-6554-5_13 · Cited by 160
Gimsing, P., Hansen, M., Knudsen, L. M., Knoblauch, P., Christensen, I. J., Ooi, C. E., & Buhl‐Jensen, P. (2008) · European Journal of Haematology · doi:10.1111/j.1600-0609.2008.01102.x · Cited by 160
Ramalingam, S. S., Belani, C. P., Ruel, C., Frankel, P., Gitlitz, B., Koczywas, M., Espinoza-Delgado, I., & Gandara, D. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318191520c · Cited by 159
Molckovsky, A., & Siu, L. L. (2008) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-1-20 · Cited by 159
Histone deacetylases: target enzymes for cancer therapy
Mottet, D., & Castronovo, V. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9131-5 · Cited by 158
Simple histone acetylation plays a complex role in the regulation of gene expression
Fukuda, H., Sano, N., Muto, S., & Horikoshi, M. (2006) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/ell032 · Cited by 156
Kuendgen, A., Knipp, S., Fox, F., Strupp, C., Hildebrandt, B., Steidl, C., Germing, U., Haas, R. R., & Gattermann, N. (2005) · Annals of Hematology · doi:10.1007/s00277-005-0026-8 · Cited by 154
A Phase II Study of Depsipeptide in Refractory Metastatic Renal Cell Cancer
Stadler, W. M., Margolin, K. A., Ferber, S., McCulloch, W. F., & Thompson, J. A. (2006) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2006.n.018 · Cited by 151
Lucas, D. M., Davis, M. E., Parthun, M. R., Mone, A. P., Kitada, S., Cunningham, K. D., Flax, E. L., Wickham, J., Reed, J. C., Byrd, J. C., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403388 · Cited by 143
Scuto, A., Kirschbaum, M., Kowolik, C., Kretzner, L., Juhasz, A., Atadja, P., Pullarkat, V., Bhatia, R., Forman, S., Yen, Y., et al. (2008) · Blood · doi:10.1182/blood-2007-10-117762 · Cited by 141 · cited 20×
“Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N, et al: The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.”
InfluentialFiskus, W., Ren, Y., Mohapatra, A., Bali, P., Mandawat, A., Rao, R., Herger, B., Yang, Y., Atadja, P., Wu, J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3093 · Cited by 140
Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies
Qian, X., LaRochelle, W. J., Ara, G., Wu, F. S.-Y., Petersen, K. D., Thougaard, A., Sehested, M., Lichenstein, H. S., & Jeffers, M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0111 · Cited by 139
Kummar, S., Gutierrez, M., Gardner, E. R., Donovan, E., Hwang, K., Chung, E. J., Lee, M.-J., Maynard, K., Kalnitskiy, M., Chen, A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0791 · Cited by 131
Klimek, V. M., Fircanis, S., Maslak, P., Guernah, I., Baum, M., Wu, N., Panageas, K., Wright, J. J., Pandolfi, P. P., & Nimer, S. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0318 · Cited by 130
Chavez-Blanco, A., Segura-Pacheco, B., Perez-Cardenas, E., Taja-Chayeb, L., Cetina, L., Candelaria, M., Cantu, D., Gonzalez-Fierro, A., Garcia-Lopez, P., Zambrano, P., et al. (2005) · Molecular Cancer · doi:10.1186/1476-4598-4-22 · Cited by 129
Camphausen, K., Scott, T., Sproull, M., & Tofilon, P. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0537 · Cited by 128
Histone deacetylase inhibitors and cancer: from cell biology to the clinic
Hess‐Stumpp, H. (2005) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2004.12.010 · Cited by 128
Edwards, A., Li, J., Atadja, P., Bhalla, K., & Haura, E. B. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0761 · Cited by 128
Buggy, J. J., Cao, Z. A., Bass, K. E., Verner, E., Balasubramanian, S., Liu, L., Schultz, B. E., Young, P. R., & Dalrymple, S. A. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0442 · Cited by 127
Berger, S. L. (2001) · Oncogene · doi:10.1038/sj.onc.1204324 · Cited by 125
From Discovery to the Coming Generation of Histone Deacetylase Inhibitors
Yoshida, M., Matsuyama, A., Komatsu, Y., & Nishino, N. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033456602 · Cited by 124
Chemical regulation of epigenetic modifications: Opportunities for new cancer therapy
Zheng, Y. G., Wu, J., Chen, Z., & Goodman, M. (2008) · Medicinal Research Reviews · doi:10.1002/med.20120 · Cited by 123
HDAC inhibitors: a potential new category of anti-tumor agents.
Li, P., Lu, J., & Huang, B. (2007) · PubMed · Cited by 121
Zhou, N., Moradei, O. M., Raeppel, S. L., Leit, S. M., Fréchette, S., Gaudette, F., Paquin, I., Bernstein, N., Bouchain, G., Vaisburg, A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800251w · Cited by 121
Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer
Martínez-Iglesias, O. A., Ruiz-Llorente, L., Sánchez‐Martínez, R., García, L. D. D., Zambrano, A., & Aranda, A. (2008) · Clinical & Translational Oncology · doi:10.1007/s12094-008-0221-x · Cited by 118
Siu, L. L., Pili, R., Duran, I., Messersmith, W. A., Chen, E. X., Sullivan, R., MacLean, M., King, S., Brown, S., Reid, G. K., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5730 · Cited by 117
Golay, J., Cuppini, L., Leoni, F., Micò, M. C., Barbui, V., Domenghini, M., Lombardi, L. T., Neri, A., Barbui, A. M., Salvi, A., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404860 · Cited by 116
Increased Affinity of c-Myb for CREB-binding Protein (CBP) after CBP-induced Acetylation
Sano, Y., & Ishii, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006896200 · Cited by 116
Histone Deacetylase Inhibitors as Novel Anticancer Therapeutics
Walkinshaw, D. R., & Yang, X. (2008) · Current Oncology · doi:10.3747/co.v15i5.371 · Cited by 114
Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin
Schrump, D. S., Fischette, M. R., Nguyen, D. M., Zhao, M., Li, X., Kunst, T. F., Hancox, A., Hong, J. A., Chen, G. A., Kruchin, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0135 · Cited by 109
Sasakawa, Y., Naoe, Y., Inoue, T., Sasakawa, T., Matsuo, M., Manda, T., & Mutoh, S. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01261-3 · Cited by 100
Histone Deacetylase Inhibitors and Anticancer Therapy
Kouraklis, G. P., & Theocharis, S. (2002) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011023353921 · Cited by 99
Bonfils, C., Kalita, A., Dubay, M., Siu, L. L., Carducci, M. A., Reid, G., Martell, R. E., Besterman, J. M., & Li, Z. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4427 · Cited by 99
Qian, X., Ara, G., Mills, E., LaRochelle, W. J., Lichenstein, H. S., & Jeffers, M. (2007) · International Journal of Cancer · doi:10.1002/ijc.23243 · Cited by 97
Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin
Schrump, D. S., Fischette, M. R., Nguyen, D. M., Zhao, M., Li, X., Kunst, T. F., Hancox, A., Hong, J. A., Chen, G. A., Kruchin, E., et al. (2007) · Clinical Lung Cancer · doi:10.1016/s1525-7304(11)70818-x · Cited by 97
Catalano, M. G., Poli, R., Pugliese, M., Fortunati, N., & Boccuzzi, G. (2007) · Endocrine Related Cancer · doi:10.1677/erc-07-0096 · Cited by 91
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer
Cang, S., Ma, Y., & Liu, D. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-22 · Cited by 90
Self-citationRecent advances of novel targeted therapy in non-small cell lung cancer
Katzel, J. A., Fanucchi, M. P., & Li, Z. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-2 · Cited by 90
Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells
Dai, Y., Chen, S., Kramer, L. B., Funk, V. L., Dent, P., & Grant, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1934 · Cited by 90
Duan, J., Friedman, J., Nottingham, L. K., Chen, Z., Ara, G., & Waes, C. V. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0285 · Cited by 82
FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities
Konstantinopoulos, P. A., Vandoros, G. P., & Papavassiliou, A. G. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0182-5 · Cited by 81
Fiskus, W. C., Rao, R., Fernandez, P., Herger, B. E., Yang, Y., Chen, J., Kolhe, R. B., Mandawat, A., Wang, Y., Joshi, R., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116319 · Cited by 81
Trus, M., Yang, L., Suárez, F., Bordeleau, L. J., Jurišica, I., & Minden, M. D. (2005) · Leukemia · doi:10.1038/sj.leu.2403773 · Cited by 80
The aggresome pathway as a target for therapy in hematologic malignancies
Simms-Waldrip, T. R., Rodríguez-González, A., Lin, T. L., Ikeda, A. K., Fu, C. H., & Sakamoto, K. M. (2008) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.03.012 · Cited by 79
Epigenetic modifications in rheumatoid arthritis
Strietholt, S., Maurer, B., Peters, M. A., Pap, T., & Gay, S. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2500 · Cited by 77
Differential protein acetylation induced by novel histone deacetylase inhibitors
Glaser, K. B., Li, J., Pease, L. J., Staver, M. J., Marcotte, P. A., Guo, J., Frey, R. R., Garland, R. B., Heyman, H. R., Wada, C. K., et al. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.10.082 · Cited by 71
Targeting Histone Deacetylases in Neuroblastoma
Witt, O., Deubzer, H., Lodrini, M., Milde, T., & Oehme, I. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787315774 · Cited by 70
Ma, B. B. Y., Sung, F. L., Tao, Q., Poon, F. F., Lui, V. W. Y., Yeo, W., Chan, S. L., & Chan, A. T. �. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9219-7 · Cited by 66
Papeleu, P., Vanhaecke, T., Elaut, G., Vinken, M., Henkens, T., Snykers, S., & Rogiers, V. (2005) · Critical Reviews in Toxicology · doi:10.1080/10408440590935639 · Cited by 64
Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro
Coffey, D. C., Kutko, M. C., Glick, R. D., Swendeman, S. L., Butler, L. M., Rifkind, R. A., Marks, P. A., Richon, V. M., & LaQuaglia, M. P. (2000) · Medical and Pediatric Oncology · doi:10.1002/1096-911x(20001201)35:6<577::aid-mpo18>3.0.co;2-3 · Cited by 62
Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Budillon, A., Gennaro, E. D., Bruzzese, F., Rocco, M., Manzo, G., & Caraglia, M. (2007) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489207780832450 · Cited by 57
Crump, M., Glück, S., Tu, D., Stewart, D., Levine, M. N., Kirkbride, P., Dancey, J. E., O'Reilly, S., Shore, T. B., Couban, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8851 · Cited by 54
Barbetti, V., Gozzini, A., Rovida, E., Morandi, A., Spinelli, E., Fossati, G., Mascagni, P., Lübbert, M., Sbarba, P. D., & Santini, V. (2007) · Oncogene · doi:10.1038/sj.onc.1210820 · Cited by 52
Schutter, H. D., Kimpe, M., Isebaert, S. F., & Nuyts, S. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.10.032 · Cited by 52
Important roles of reversible acetylation in the function of hematopoietic transcription factors
Huo, X., & Zhang, J. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00340.x · Cited by 42
Apoptotic Cytotoxic Effects of a Histone Deacetylase Inhibitor, FK228, on Malignant Lymphoid Cells
Murata, M., Towatari, M., Kosugi, H., Tanimoto, M., Ueda, R., Saito, H., & Naoe, T. (2000) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2000.tb00899.x · Cited by 40
Qu, W., Kang, Y., Zhou, M.-S., Fu, L., Hua, Z., & Wang, L. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.11.018 · Cited by 37
Valproate enhances imatinib‐induced growth arrest and apoptosis in chronic myeloid leukemia cells
Morotti, A., Cilloni, D., Messa, F., Arruga, F., Defilippi, I., Carturan, S., Catalano, R., Rosso, V., Chiarenza, A., Pilatrino, C., et al. (2006) · Cancer · doi:10.1002/cncr.21725 · Cited by 36
HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics
Paola, Gallinari, Di, Marco, M. D., Phillip, Jones, Michèle, Pallaoro, Christian, C., & Steinkühler (2007) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 35
Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors
Haefner, M., Blüthner, T., Niederhagen, M., Moebius, C., Wittekind, C., Mössner, J., Caca, K., & Wiedmann, M. W. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3681 · Cited by 34
Balakin, K. V., Ivanenkov, Y. A., Kiselyov, A. S., & Tkachenko, S. E. (2007) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152007781668698 · Cited by 31
Kim, J. C., Kim, D. D., Lee, Y. M., Kim, T. W., Cho, D. H., Kim, M. B., Ro, S. G., Kim, S., Kim, S., & Lee, J. S. (2008) · International Journal of Colorectal Disease · doi:10.1007/s00384-008-0590-1 · Cited by 26
Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor
Tourneau, C. L., & Siu, L. L. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.8.1247 · Cited by 26
The Changing Face of HDAC Inhibitor Depsipeptide
Zhou, W., & Zhu, W. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909787314039 · Cited by 24
Dejligbjerg, M., Grauslund, M., Christensen, I. J., Tjørnelund, J., Jensen, P. B., & Sehested, M. (2008) · Cancer Biomarkers · doi:10.3233/cbm-2008-4206 · Cited by 21
Phase I trial of 5-azacitidine (5AC) and SNDX-275 in advanced lung cancer (NSCLC)
Juergens, R. A., Vendetti, F. P., Coleman, B., Sebree, R., Rudek, M. A., Belinsky, S. A., Brock, M. V., Herman, J. G., Baylin, S. B., & Rudin, C. M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.19036 · Cited by 12
Biologists abandon Popper at their peril
(2000) · doi:10.1002/(sici)1521-1878(200002)22:2
Cited by
Yardley, D. A., Ismail-Khan, R. R., Melichar, B., Lichinitser, M., Munster, P. N., Klein, P. M., Cruickshank, S., Miller, K. D., Lee, M. J., & Trepel, J. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7251 · Cited by 423
Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To Succeed
Gryder, B. E., Sodji, Q. H., & Oyelere, A. K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.3 · Cited by 404
Targeting the correct HDAC(s) to treat cognitive disorders
Fischer, A., Sananbenesi, F., Mungenast, A., & Tsai, L.-H. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.09.003 · Cited by 354
Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy
Ramaiah, M. J., Tangutur, A. D., & Manyam, R. R. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119504 · Cited by 345
HIV-1 transcription and latency: an update
Van Lint, C., Bouchat, S., & Marcello, A. (2013) · Retrovirology · doi:10.1186/1742-4690-10-67 · Cited by 338
Metadata
- Authors
- Tan, J., Cang, S., Ma, Y., Petrillo, R. L., & Liu, D.
- Venue
- Journal of Hematology & Oncology
- Published
- 2010-02-04
- Volume
- 3
- Issue
- 1
- Pages
- 5-5
- ISSN
- 1756-8722 (ISSN-L)
- OpenAlex
- W2158178080
- Cited by
- 425
- References
- 131
- FWCI
- 23.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.